What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?

What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?

What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Nir Peled, MD, PhD, FCCP

Professor Nir Peled, MD, PhD, FCCP

Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel